Bionomics Limited (ASX:BNO)

Dr Errol De Souza
Executive Chairman
Market Cap (AUD): 62.25M
Sector: Health Care
Last Trade (AUD): 0.055 +0.01 (+19.57%)
Tab Bar

1. About

Bionomics Limited (ASX:BNO) is a clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates.

Bionomics’ lead drug candidate BNC210 is currently in development for initiation of a second Phase 2 trial for the treatment of PTSD and is a novel, proprietary negative allosteric modulator of the alpha-7 (α7) nicotinic acetylcholine receptor.

Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc.

2. Business model

3. Strategy

4. Markets

5. Competition

6. History

7. Team

8. Financials

9. Risk